MARKET

SPRO

SPRO

Spero Therapeuti
NASDAQ
0.7899
+0.0114
+1.46%
Opening 13:07 03/14 EDT
OPEN
0.7726
PREV CLOSE
0.7785
HIGH
0.7955
LOW
0.7726
VOLUME
12.63K
TURNOVER
--
52 WEEK HIGH
1.890
52 WEEK LOW
0.7300
MARKET CAP
43.06M
P/E (TTM)
12.97
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SPRO last week (0303-0307)?
Weekly Report · 4d ago
Spero Therapeutics Inc <SPRO.OQ> expected to post a loss of 31 cents a share - Earnings Preview
Reuters · 03/07 11:18
Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Tops Revenue Estimates
NASDAQ · 03/03 13:10
Weekly Report: what happened at SPRO last week (0224-0228)?
Weekly Report · 03/03 09:18
UPDATE – Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference
Barchart · 02/25 09:15
Weekly Report: what happened at SPRO last week (0217-0221)?
Weekly Report · 02/24 09:19
Citizens JMP healthcare analysts hold an analyst/industry conference call
TipRanks · 02/18 20:50
Weekly Report: what happened at SPRO last week (0210-0214)?
Weekly Report · 02/17 09:18
More
About SPRO
More
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections with unmet need. Its lead product candidate, SPR720, is an oral antimicrobial agent in development for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease, a rare orphan disease. Its partnership-directed programs consist of tebipenem HBr and SPR206. The tebipenem HBr is designed to be the oral carbapenem-class antibiotic for use to treat certain bacterial infections that cause complicated urinary tract infections (cUTIs), including pyelonephritis, caused by certain microorganisms, in adult patients who have limited oral treatment options. SPR206 is a direct acting intravenous (IV)-administered product candidate being developed as an option to treat MDR Gram-negative bacterial infections in the hospital setting.
Recently
Symbol
Price
%Change

Webull offers Spero Therapeutics Inc stock information, including NASDAQ: SPRO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SPRO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SPRO stock methods without spending real money on the virtual paper trading platform.